Lunit, Summit team up on AI biomarkers for cancer drug

Korean medical AI firm Lunit will work with Summit Therapeutics, applying its Lunit Scope IO pathology platform to find biomarkers tied to treatment response for the dual-antibody drug ibonesimab, helping select likely responders. Summit is developing the PD-1/VEGF candidate globally.

• AstraZeneca, insitro sign up to $1.5B AI drug discovery deal2026-10-15
• Nordics Accelerate AI Infrastructure Expansion2026-10-15